# Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

> **NCT07104110** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** QLH12016
- **DRUG:** abiraterone acetate
- **DRUG:** enzalutamide

## Key facts

- **NCT ID:** NCT07104110
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2027-10
- **Final completion:** 2028-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07104110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07104110, "Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07104110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*